Log in to save to my catalogue

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic...

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1952661015

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers

About this item

Full title

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers

Publisher

United States: Public Library of Science

Journal title

PloS one, 2017-10, Vol.12 (10), p.e0185753-e0185753

Language

English

Formats

Publication information

Publisher

United States: Public Library of Science

More information

Scope and Contents

Contents

The Prosigna® breast cancer prognostic gene signature assay identifies a gene-expression profile that permits the classification of tumors into subtypes and gives a score for the risk of recurrence (ROR) at 10 years. The primary objective of this multicenter study was to evaluate the impact of Prosigna's assay information on physicians' adjuvant tr...

Alternative Titles

Full title

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_1952661015

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1952661015

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0185753

How to access this item